Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Low-dose abiraterone plus Olaparib as a late-line treatment for mCRPC patients without BRCA1/2 mutations: a multicenter retrospective pilot study.

Scientific reports - 27 Aug 2024

Chen Sijin, Zhong Dewen, Yu Chenbo, Cai Desheng, Wei Qichen, Yang Minggen, Li Tao, Zhu Qingguo, Ye Liefu, Wei Yongbao, Wu Jinfeng

Abstract excerpt

Although overall survival data are still premature, the PROpel study found radiological progression-free survival (PFS) benefits of abiraterone and olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC). However, for patients who have not been genetically tested or lack BRCA1/2 mutations (BRCAm), this combination therapy has been questioned as a first-line conventional treatment for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Androstenes
Share to BRCA2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Phthalazines

Share to Pilot Projects

Share to Piperazines

Share to Progression-Free Survival

Share to Prostate-Specific Antigen

Share to Prostatic Neoplasms, Castration-Resistant

Source

Open in PubMed Open full text

Identifiers

PMID: 39191899
DOI: 10.1038/s41598-024-70398-3
PMCID: PMC11349984

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Low-dose abiraterone plus Olaparib as a late-line treatment for mCRPC patients without BRCA1/2 mutations: a multicenter retrospective pilot study.PMID 39191899Read ↗

Olaparib monotherapy or in combination with abiraterone for treating mutated metastatic castration-resistant prostate cancer: alone or stronger together?Semantic proximity Read ↗

Olaparib for Metastatic Castration-Resistant Prostate CancerSemantic proximity Read ↗

Olaparib combined with abiraterone in HRR-mutated metastatic hormone-sensitive prostate cancer: a single-arm phase II trial.Semantic proximity Read ↗

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.Semantic proximity Read ↗

PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: Unraveling the Therapeutic LandscapeSemantic proximity Read ↗

Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.Semantic proximity Read ↗

Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2 , or ATM Alterations Identified by Testing Circulating Tumor DNASemantic proximity Read ↗

Olaparib in Patients With Metastatic Prostate Cancer With BRCA1/2 Mutation: Results From the TAPUR Study.Semantic proximity Read ↗

Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient SelectionSemantic proximity Read ↗

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.Semantic proximity Read ↗

A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer.Semantic proximity Read ↗

Olaparib in patients with mCRPC with homologous recombination repair gene alterations: PROfound Asian subset analysisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.